Stay updated on Ibrutinib & PD-1 Blockade in High Risk CLL Clinical Trial
Sign up to get notified when there's something new on the Ibrutinib & PD-1 Blockade in High Risk CLL Clinical Trial page.

Latest updates to the Ibrutinib & PD-1 Blockade in High Risk CLL Clinical Trial page
- Check4 days agoNo Change Detected
- Check12 days agoChange DetectedThe page's revision label was updated from v3.6.2 to v3.6.3 in the footer. This represents a minor site version update and does not alter any study details or page content.SummaryDifference0.1%

- Check19 days agoChange DetectedA new Revision tag shows v3.6.2 on the page, replacing v3.6.0, indicating a minor update to the page template or backend. No visible study information or actions appear to be changed.SummaryDifference0.1%

- Check33 days agoChange DetectedRecruitment status on the study page now indicates 'No longer looking for participants', signaling that enrollment is closed. New help and navigation sections were added (How to Read a Study Record, Common Questions, How to Join a Study), and the Intervention/Treatment header formatting was standardized, accompanied by a revision note (Revision: v3.6.0).SummaryDifference0.6%

- Check40 days agoChange DetectedFooter area updated to include a Moffitt Cancer Center Clinical Trials website link and the sponsor's institution name (H. Lee Moffitt Cancer Center and Research Institute), along with a 'Helpful Links Provided by' label. The page revision tag was updated from v3.5.4 to v3.5.5.SummaryDifference0.2%

- Check47 days agoChange DetectedThe deletions remove sponsor attribution blocks for the study (H. Lee Moffitt Cancer Center and Research Institute) and the reference to the Moffitt Clinical Trials website, as well as the 'Helpful Links Provided by' label. This changes how attribution and related navigation are presented on the page.SummaryDifference0.2%

- Check61 days agoChange DetectedThe page now shows Revision: v3.5.4, replacing the previous v3.5.3 label. This indicates a backend/template update to the study record display without changing substantive study details.SummaryDifference0.1%

Stay in the know with updates to Ibrutinib & PD-1 Blockade in High Risk CLL Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ibrutinib & PD-1 Blockade in High Risk CLL Clinical Trial page.